XML 45 R29.htm IDEA: XBRL DOCUMENT v3.25.4
Balance Sheet Details (Tables)
12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory
Inventory consisted of the following:
December 31,
2025
December 31, 2024
Raw materials$— $— 
Work in process2,004 — 
Finished goods18 — 
$2,022 $— 
Schedule of Components of Prepaid Expenses and Other Current Assets
Prepaid expenses and other assets consisted of the following:
December 31,
2025
December 31,
2024
Prepaid clinical costs$19,547 $6,842 
Interest receivable7,758 8,310 
Deferred compensation plan3,249 829 
Prepaid research and development costs2,901 714 
Loyal preferred stock (Note 8)
2,000 2,000 
Prepaid subscriptions1,255 2,561 
Other3,456 2,392 
Total prepaid expenses and other assets40,166 23,648 
Less prepaid expenses and other current assets(17,839)(20,819)
Prepaid expenses and other assets, net of current portion$22,327 $2,829 
Schedule of Components of Property and Equipment, Net
Property and equipment, net consisted of the following:
December 31,
2025
December 31,
2024
Leasehold improvements$10,003 $11,900 
Lab equipment9,960 5,693 
Office equipment2,225 2,147 
Computers and software60 60 
Property and equipment at cost22,248 19,800 
Less accumulated depreciation and amortization(7,952)(7,732)
Total$14,296 $12,068 
Schedule of Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consisted of the following:
December 31,
2025
December 31, 2024
Accounts payable$22,611 $5,853 
Accrued clinical trial costs7,369 3,076 
Accrued research and development costs4,506 6,067 
Accrued outside services and professional fees4,430 5,572 
Other accrued expenses2,854 901 
Total$41,770 $21,469